Premium
Anti‐Interleukin‐ 6 Therapy Decreases Hip Synovitis and Bone Resorption and Increases Bone Formation Following Ischemic Osteonecrosis of the Femoral Head
Author(s) -
Ren Yinshi,
Deng Zhuo,
Gokani Vishal,
Kutschke Michael,
Mitchell Thomas Wesley,
Aruwajoye Olumide,
Adapala Naga Suresh,
Kamiya Nobuhiro,
AbuAmer Yousef,
Kim Harry KW
Publication year - 2021
Publication title -
journal of bone and mineral research
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.882
H-Index - 241
eISSN - 1523-4681
pISSN - 0884-0431
DOI - 10.1002/jbmr.4191
Subject(s) - medicine , synovitis , bone resorption , femoral head , resorption , bone remodeling , pathology , surgery , rheumatoid arthritis
Legg‐Calvé‐Perthes disease (LCPD) is a juvenile form of ischemic femoral head osteonecrosis, which produces chronic hip synovitis, permanent femoral head deformity, and premature osteoarthritis. Currently, there is no medical therapy for LCPD. Interleukin‐6 (IL‐6) is significantly elevated in the synovial fluid of patients with LCPD. We hypothesize that IL‐6 elevation promotes chronic hip synovitis and impairs bone healing after ischemic osteonecrosis. We set out to test if anti‐IL‐6 therapy using tocilizumab can decrease hip synovitis and improve bone healing in the piglet model of LCPD. Fourteen piglets were surgically induced with ischemic osteonecrosis and assigned to two groups: the no treatment group ( n = 7) and the tocilizumab group (15 to 20 mg/kg, biweekly intravenous injection, n = 7). All animals were euthanized 8 weeks after the induction of osteonecrosis. Hip synovium and femoral heads were assessed for hip synovitis and bone healing using histology, micro‐CT, and histomorphometry. The mean hip synovitis score and the number of synovial macrophages and vessels were significantly lower in the tocilizumab group compared with the no treatment group ( p < .0001, p = .01, and p < .01, respectively). Micro‐CT analysis of the femoral heads showed a significantly higher bone volume in the tocilizumab group compared with the no treatment group ( p = .02). The histologic assessment revealed a significantly lower number of osteoclasts per bone surface ( p < .001) in the tocilizumab group compared with the no treatment group. Moreover, fluorochrome labeling showed a significantly higher percent of mineralizing bone surface ( p < .01), bone formation rate per bone surface ( p < .01), and mineral apposition rate ( p = .04) in the tocilizumab group. Taken together, tocilizumab therapy decreased hip synovitis and osteoclastic bone resorption and increased new bone formation after ischemic osteonecrosis. This study provides preclinical evidence that tocilizumab decreases synovitis and improves bone healing in a large animal model of LCPD. © 2020 American Society for Bone and Mineral Research (ASBMR).